HSDTHIGH SIGNALFINANCIAL10-K

HSDT underwent a massive financial transformation with stockholders' equity surging 28,315% to $300.9M while operating losses exploded to -$243.8M, suggesting a major capital raise accompanied by significant operational scaling challenges.

The dramatic increase in stockholders' equity and total assets indicates a substantial capital infusion, likely through equity financing or a major transaction, which provided the company with significantly enhanced financial resources. However, the concurrent explosion in operating losses from -$13.9M to -$243.8M despite revenue growth suggests the company is investing heavily in expansion or facing operational scaling difficulties that investors should monitor closely.

Comparing 2026-03-31 vs 2025-03-25View on EDGAR →
FINANCIAL ANALYSIS

HSDT experienced a complete financial metamorphosis with total assets growing 8,481% to $303.9M and stockholders' equity increasing 28,315% to $300.9M, clearly indicating a major capital event. While revenue surged 1,057% to $6.0M and the company achieved positive gross profit of $5.5M, operating losses ballooned from -$13.9M to -$243.8M due to more than doubling of SG&A expenses, suggesting aggressive expansion spending. The overall picture shows a company that has secured substantial funding but is burning through capital rapidly in pursuit of growth, creating both opportunity and risk for investors.

FINANCIAL STATEMENT CHANGES
Stockholders Equity
Balance Sheet
+28314.8%
$1.1M$300.9M

Equity base grew 28314.8% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Gross Profit
P&L
+8998.4%
-$62K$5.5M

Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.

Total Assets
Balance Sheet
+8480.7%
$3.5M$303.9M

Asset base grew 8480.7% — expansion through organic growth, acquisitions, or capital deployment.

Operating Income
P&L
-1653.9%
-$13.9M-$243.8M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

Revenue
P&L
+1057.1%
$520K$6.0M

Strong top-line growth of 1057.1% — accelerating demand or successful expansion into new markets.

Current Assets
Balance Sheet
+809.9%
$3.4M$31.2M

Current assets grew 809.9% — improving short-term liquidity or inventory/receivables build.

Cash & Equivalents
Balance Sheet
+569.3%
$1.1M$7.3M

Cash position surged 569.3% — strong cash generation or capital raise providing significant financial cushion.

Net Income
P&L
-248.2%
-$11.7M-$40.9M

Net income declined 248.2% — review whether driven by operations, interest costs, or non-recurring items.

SG&A Expense
P&L
+128.6%
$10.1M$23.1M

SG&A up 128.6% — significant increase in sales or administrative costs, monitor impact on operating leverage.

Capital Expenditure
Cash Flow
-82.8%
$29K$5K

Capex reduced 82.8% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

LANGUAGE CHANGES
NEW — 2026-03-31
PRIOR — 2025-03-25
ADDED
As of March 27, 2026, there were 55,034,047 shares of the registrant s Class A common stock outstanding.
( Marvel ), Solana Company (Hong Kong) Limited ( SCHK ), Helius Medical, Inc.
FORWARD-LOOKING STATEMENTS This Form 10-K includes forward-looking statements that involve risks and uncertainties, including statements regarding the Company s market, strategy, competition, capital needs, business plans and expectations.
In some cases, you can identify forward-looking statements by terminology such as may, will, should, expect, plan, intend, anticipate, believe, estimate, predict, potential, continue, or the negative of such terms or other comparable terminology.
Food and Drug Administration ( FDA ), filings and their subsequent approvals, other foreign or domestic regulatory filings; the safety and effectiveness of our product; our market awareness; our ability to compete effectively; the ability and limitation of our manufacturing sources; our distribution network; the adequacy of our intellectual property protection; our future patent approvals; our future expenses and cash flow; our ability to become profitable; our future financing arrangements; and any future stock price.
+7 more — sign up free →
REMOVED
As of March 18, 2025, there were 6,126,778 shares of the registrant s Class A common stock outstanding.
All statements contained herein that are not clearly historical in nature are forward-looking and the words anticipate, believe, calls for, could depends, estimate, expect, extrapolate, foresee, goal, intend, likely, might, plan, project, propose, potential, target, think, and similar expressions, or that events or conditions may, should occur will, would, or any similar expressions are generally intended to identify forward-looking statements.
The forward-looking statements in this Form 10-K include but are not limited to statements relating to: the Company s future growth and operational progress, including manufacturing activities for the PoNS device, receipt of prescriptions and progress of commercialization of the PoNS device in the U.S., our ability to receive adequate reimbursement coverage under Medicare, Medicaid or under other insurance plans, clinical development plans, product development activities, plans for U.S.
Such forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by Helius, are inherently subject to significant business, economic, competitive political and social uncertainties and contingencies.
Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →